CD14 is a key mediator of both lysophosphatidic acid and lipopolysaccharide induction of foam cell formation

J Biol Chem. 2017 Sep 1;292(35):14391-14400. doi: 10.1074/jbc.M117.781807. Epub 2017 Jul 13.

Abstract

Macrophage uptake of oxidized low-density lipoprotein (oxLDL) plays an important role in foam cell formation and the pathogenesis of atherosclerosis. We report here that lysophosphatidic acid (LPA) enhances lipopolysaccharide (LPS)-induced oxLDL uptake in macrophages. Our data revealed that both LPA and LPS highly induce the CD14 expression at messenger RNA and protein levels in macrophages. The role of CD14, one component of the LPS receptor cluster, in LPA-induced biological functions has been unknown. We took several steps to examine the role of CD14 in LPA signaling pathways. Knockdown of CD14 expression nearly completely blocked LPA/LPS-induced oxLDL uptake in macrophages, demonstrating for the first time that CD14 is a key mediator responsible for both LPA- and LPS-induced oxLDL uptake/foam cell formation. To determine the molecular mechanism mediating CD14 function, we demonstrated that both LPA and LPS significantly induce the expression of scavenger receptor class A type I (SR-AI), which has been implicated in lipid uptake process, and depletion of CD14 levels blocked LPA/LPS-induced SR-AI expression. We further showed that the SR-AI-specific antibody, which quenches SR-AI function, blocked LPA- and LPS-induced foam cell formation. Thus, SR-AI is the downstream mediator of CD14 in regulating LPA-, LPS-, and LPA/LPS-induced foam cell formation. Taken together, our results provide the first experimental evidence that CD14 is a novel connecting molecule linking both LPA and LPS pathways and is a key mediator responsible for LPA/LPS-induced foam cell formation. The LPA/LPS-CD14-SR-AI nexus might be the new convergent pathway, contributing to the worsening of atherosclerosis.

Keywords: CD14; gene regulation; lipid signaling; macrophage; signal transduction; vascular biology.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Absorption, Physiological / drug effects
  • Animals
  • Biomarkers / metabolism
  • Bone Marrow Cells / cytology
  • Cells, Cultured
  • Foam Cells / drug effects
  • Foam Cells / immunology
  • Foam Cells / metabolism*
  • Foam Cells / pathology
  • Gene Expression Regulation / drug effects*
  • Humans
  • Isoxazoles / pharmacology
  • Lipopolysaccharide Receptors / chemistry
  • Lipopolysaccharide Receptors / genetics
  • Lipopolysaccharide Receptors / metabolism*
  • Lipopolysaccharides / toxicity
  • Lipoproteins, LDL / metabolism
  • Lysophospholipids / metabolism*
  • Macrophages / cytology
  • Macrophages / drug effects
  • Macrophages / immunology
  • Macrophages / metabolism*
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Microscopy, Fluorescence
  • Propionates / pharmacology
  • RNA Interference
  • Receptors, Lysophosphatidic Acid / agonists*
  • Receptors, Lysophosphatidic Acid / antagonists & inhibitors
  • Receptors, Lysophosphatidic Acid / genetics
  • Receptors, Lysophosphatidic Acid / metabolism
  • Scavenger Receptors, Class A / agonists
  • Scavenger Receptors, Class A / antagonists & inhibitors
  • Scavenger Receptors, Class A / genetics
  • Scavenger Receptors, Class A / metabolism*

Substances

  • 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl amino)-3-methyl-5-isoxazolyl) benzylsulfanyl) propanoic acid
  • Biomarkers
  • Isoxazoles
  • Lipopolysaccharide Receptors
  • Lipopolysaccharides
  • Lipoproteins, LDL
  • Lysophospholipids
  • Msr1 protein, mouse
  • Propionates
  • Receptors, Lysophosphatidic Acid
  • Scavenger Receptors, Class A
  • oxidized low density lipoprotein
  • lysophosphatidic acid